Abstract 1867: Development and validation of fluorescent lipid nanoparticles for RNA delivery applicable to personalized in vitro oncology models

Abstract Tebubio offers contract services in RNA-based therapeutic discovery, in vitro modeling, biomarker mapping, and data analysis. Leveraging these platforms, we have developed innovative lipid nanoparticles (LNPs) designed to encapsulate and deliver RNA. This advancement features a fluorescent lipid, created by Echelon Inc., which enables imaging-based tracking of the LNPs. Using this fluorescent lipid, we formulated LNPs encapsulating a mRNA Coding for a fluorescent protein. We validated the distribution of these LNPs within 2D mammalian cell line model and confirmed RNA expression in these cells through imaging techniques. This technology is applicable to in vitro oncology models, including patient-derived spheroids and tumoroids, which allow for a personalized approach to therapeutic testing. Ultimately, Tebubio’s platform provides end-to-end support, from RNA optimization and custom LNP formulation to efficacy validation in vitro, enabling personalized medicine models for RNA-based therapeutics. Citation Format: Xavier Warnet, Célia Bosso-Lefèvre, Erica Cirri, Eric Mennesson, Marie Morin, Mélanie Sapateiro, Maxime Rochet, Laetitia Edmond, Alexandra Foucher, Armelle Vindrios, Alzbeta Komarkova, Flavien Carpenier, Romain Cordonnier-Goulay. Development and validation of fluorescent lipid nanoparticles for RNA delivery applicable to personalized in vitro oncology models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1867.